Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Vaxigrip NH 2007-2008
NCT00491257Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2007
- Primary completion
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Vaxigrip in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Immunogenicity of 2007-2008 Influenza vaccine at 21 days. Started Jun 2007; status: completed.
02
Drugs
Vaxigrip
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00491257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491257.